On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Globant S.A. (NYSE:GLOB), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Intrexon Corporation (NYSE:XON), Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL)

Globant S.A. (NYSE:GLOB), with shares gained 13.89%, closed at $21.07, hitting new 52-week high of $21.11.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), with shares jumped 11.45%, settled at $128.78, hitting new 52-week high of $133.54.

Intrexon Corporation (NYSE:XON), with shares climbed 9.22%, and closed at $43.

Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL), surged 8.67%, and closed at $2.13.

Latest NEWS regarding these Stocks are depicted underneath:

Globant S.A. (NYSE:GLOB)

Globant S.A. (GLOB), declared the pricing of its secondary public offering of 3,473,382 ordinary shares by certain of its shareholders, which represents a 20% raise in the amount of shares offered over the 2,906,266 ordinary shares declared at the commencement of the offering on March 23, 2015. The ordinary shares were sold to the public at a price of $18.50 per share. The closing price of the Corporation’s ordinary shares on March 26, 2015 was $18.50 per share. The Corporation will not receive any proceeds from the sale of ordinary shares by the selling shareholders.

The underwriters of the offering have a 30-day option to purchase up to an additional 521,008 ordinary shares from certain of the selling shareholders.

J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. William Blair & Corporation, L.L.C., Cowen and Corporation, LLC and LOYAL3 Securities, Inc. are acting as co-managers for the offering.

Globant S.A. develops software solutions in North America, Europe, Latin America, and internationally. The corporation offers content administration systems that are designed to allow rich content editing and immediate publishing of up-to-date product data and other information; and e-commerce applications to generate traffic and new sales, and incorporate product catalogs, payment and checkout functions, micro-transactions, search engine marketing, search engine optimization, and reporting, in addition to designs and builds portals.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Formerly on March 18, BioMarin Pharmaceutical Inc. (BMRN), declared that on March 16, 2015, the compensation committee of BioMarin’s board of directors approved the grant to 31 newly hired employees of 10,480 restricted share units in the aggregate.

The restricted share units were granted following the BioMarin Pharmaceutical Inc. 2014 Inducement Plan, approved by the compensation committee of BioMarin’s board of directors on December 17, 2014, and were granted as inducements material to the new employees entering into employment with BioMarin in accordance with NASDAQ Listing Rule 5635(c)(4).

The restricted share units will vest in equal installments annually over four years on the anniversary of the grant date, assuming in each case the employee remains continuously employed by BioMarin as of such date. BioMarin is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.

Intrexon Corporation (NYSE:XON)

Soligenix, an exclusive worldwide partner of Intrexon Corporation (XON), declared recent accomplishments and financial results for the year ended December 31, 2014.

Financial Results – Year Ended December 31, 2014:

Soligenix’s proceeds for the year ended December 31, 2014 were $7.0 million as contrast to $3.2 million for the preceding year. Proceeds comprised of contracts with the US Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) and the NIAID in support of OrbeShield™ (oral beclomethasone 17,21-dipropionate or BDP) development in the treatment of GI ARS. In addition, during the third quarter of 2014, the Corporation was awarded a contract with NIAID to advance the development of RiVax™, its proprietary ricin toxin vaccine, in conjunction with its heat stabilization technology, ThermoVax™, as a medical countermeasure to prevent the effects of ricin exposure.

Soligenix’s basic net loss was $6.7 million, or $0.32 per share, as contrast to $10.1 million, or $0.65 per share, for the year ended December 31, 2014 and 2013 respectively. Comprised of in the net loss for years ended December 31, 2014 and 2013 is a non-cash gain of $3.4 million and a non-cash loss of $(3.7) million, respectively. This non-cash item reflects the change in fair value of the liability related to warrants issued in the Corporation’s June 25, 2013 registered public offering and is comprised of in other revenue/(expense).

Research and development expenses, counting attained in-process research and development, were $9.1 million as contrast to $5.1 million for the year ended December 31, 2014 and 2013, respectively. For the year ended December 31, 2014, the raise of $4.0 million is attributable to the asset attainment of SGX301, synthetic hypericin, from Hy BioPharma paid in the form of $0.25 million in cash and $3.75 million in restricted ordinary stock.

General and administrative expenses were $3.4 million as contrast to $2.8 million for the year ended December 31, 2014 and 2013, respectively. This raise is primarily related to an raise in headcount and an raise in outside professional fees.

As of December 31, 2014, the Corporation’s cash position was $5.5 million.

Intrexon Corporation, a biotechnology corporation, operates in the synthetic biology field in the United States. The corporation, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.

Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL)

Formerly on March 16, Hanwha Q CELLS Co., Ltd. (HQCL), declared that its US entity has signed a $20 million three-year Senior Secured Revolving Credit Facility with Wells Fargo Capital Finance. The credit line will be used for working capital and other general corporate purposes.

Hanwha Q CELLS Investment Co., Ltd. manufactures solar cells and modules, solar system solutions, and power plants. The corporation is based in Cayman Islands. The corporation operates as a partner of Hanwha Solar Holdings Co., Ltd.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.